Assunta Esposito

发表

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

G. Madonna, P. Ascierto, D. Galati, 2020, Journal of Translational Medicine.

Serious haematological toxicity during and after ipilimumab treatment: a case series

P. Ascierto, E. Simeone, N. Mozzillo, 2014, Journal of Medical Case Reports.

24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome

G. Madonna, D. Mallardo, P. Ascierto, 2021, Journal for ImmunoTherapy of Cancer.

Melanoma immunotherapy: strategies to overcome pharmacological resistance

P. Ascierto, L. Scarpato, M. Vitale, 2020, Expert review of anticancer therapy.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

F. Fulciniti, G. Botti, P. Ascierto, 2014, Cancer Immunology, Immunotherapy.

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

P. Ascierto, G. Ciliberto, E. Simeone, 2014, Oncoimmunology.

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

P. Ascierto, E. Simeone, D. Giannarelli, 2015, Journal of Immunotherapy for Cancer.

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

K. Flaherty, G. Madonna, D. Mallardo, 2021, Journal of translational medicine.

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

F. Fulciniti, G. Botti, P. Ascierto, 2014, Cancer Immunology, Immunotherapy.

Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.

P. Ascierto, E. Simeone, P. Queirolo, 2012 .

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

P. Ascierto, E. Simeone, G. Palmieri, 2017, Oncoimmunology.

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

D. Mallardo, P. Ascierto, S. Warren, 2022, Journal for immunotherapy of cancer.

Do BRAF inhibitors select for populations with different disease progression kinetics?

P. Ascierto, E. Simeone, G. Palmieri, 2013, Journal of Translational Medicine.

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

G. Madonna, P. Ascierto, D. Galati, 2020, Journal of Translational Medicine.